These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. Anderson AM; Jang JH; Easley KA; Fuchs D; Gisslen M; Zetterberg H; Blennow K; Ellis RJ; Franklin D; Heaton RK; Grant I; Letendre SL J Acquir Immune Defic Syndr; 2020 Dec; 85(5):617-625. PubMed ID: 32932412 [TBL] [Abstract][Full Text] [Related]
9. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study. Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Ceruloplasmin, Haptoglobin, and Vascular Endothelial Growth Factor Are Associated with Neurocognitive Impairment in Adults with HIV Infection. Kallianpur AR; Gittleman H; Letendre S; Ellis R; Barnholtz-Sloan JS; Bush WS; Heaton R; Samuels DC; Franklin DR; Rosario-Cookson D; Clifford DB; Collier AC; Gelman B; Marra CM; McArthur JC; McCutchan JA; Morgello S; Grant I; Simpson D; Connor JR; Hulgan T; Mol Neurobiol; 2019 May; 56(5):3808-3818. PubMed ID: 30209774 [TBL] [Abstract][Full Text] [Related]
11. Anemia and Erythrocyte Indices Are Associated With Neurocognitive Performance Across Multiple Ability Domains in Adults With HIV. Okwuegbuna OK; Kaur H; Jennifer I; Bush WS; Bharti A; Umlauf A; Ellis RJ; Franklin DR; Heaton RK; McCutchan JA; Kallianpur AR; Letendre SL J Acquir Immune Defic Syndr; 2023 Apr; 92(5):414-421. PubMed ID: 36580636 [TBL] [Abstract][Full Text] [Related]
12. Increased cell-free mitochondrial DNA is a marker of ongoing inflammation and better neurocognitive function in virologically suppressed HIV-infected individuals. Pérez-Santiago J; De Oliveira MF; Var SR; Day TRC; Woods SP; Gianella S; Mehta SR J Neurovirol; 2017 Apr; 23(2):283-289. PubMed ID: 27921220 [TBL] [Abstract][Full Text] [Related]
13. Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch. Tiraboschi JM; Muñoz-Moreno JA; Puertas MC; Alonso-Villaverde C; Prats A; Ferrer E; Rozas N; Maso M; Ouchi D; Martinez-Picado J; Podzamczer D HIV Med; 2015 Jul; 16(6):388-92. PubMed ID: 25721471 [TBL] [Abstract][Full Text] [Related]
15. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). Merlini E; Iannuzzi F; Calcagno A; Bai F; Trunfio M; d'Arminio Monforte A; Bonora S; Marchetti G J Neurovirol; 2018 Dec; 24(6):679-694. PubMed ID: 29987585 [TBL] [Abstract][Full Text] [Related]
16. Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders. Barco A; Orlando S; Stroffolini G; Pirriatore V; Lazzaro A; Vai D; Guastamacchia G; Noce G; Atzori C; Trunfio M; Bonora S; Di Perri G; Calcagno A J Neurovirol; 2022 Apr; 28(2):226-235. PubMed ID: 35044644 [TBL] [Abstract][Full Text] [Related]
17. The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease. Rubin LH; Sundermann EE; Moore DJ J Neurovirol; 2019 Oct; 25(5):661-672. PubMed ID: 30671777 [TBL] [Abstract][Full Text] [Related]